Spruce Biosciences, Inc.

SPRB Healthcare Biotechnology

Spruce Biosciences, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $4.9 million, down 51.3% from fiscal 2023. In the quarter to June 2026, revenue fell 75.9%, EPS fell 90.9%, free cash flow fell 152.1% and total debt rose 427.2%, each against the same quarter a year earlier.

39.65 1.82 −4.39%
Market cap
$119.2M
P/E
0.0×
Fwd P/E
−2.3×
Dividend yield
—
F-score
n/a
Altman Z
36.60
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
1.54 5.17 4.67 9.23
Net Debt/EBITDA
1.23 4.41 4.06 5.62
Debt/Equity
0.10 0.00 0.19 0.08
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(9.44) (8.42) (6.37) (9.15)
Book value per Share
9.57 55.43 25.25 34.44
Free Cash Flow
(5.32) (6.46) (8.74) (22.25)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates